A Systems Biology Approach To Defining Therapeutic Targets In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$633,112.00
Summary
Breast cancer is a very complex disease affecting large numbers of women. Current treatment strategies are effective at controlling the disease for patients, however many continue to be burdened by their disease as their tumour either does not respond or develops resistance to the treatment. We will use mathematical approaches to analyse large and complex data sets generated from breast cancers to identify new therapeutic targets and improve patient outcomes.
Functional Characterization And Therapeutic Targeting Of The Novel Long Noncoding RNA RP1-40E16.9
Funder
National Health and Medical Research Council
Funding Amount
$673,447.00
Summary
Cancer is the most common cause of death from diseases in children. Neuroblastoma is the most common solid tumour in early childhood. In this project, we will define the role of a novel long non-protein-coding RNA in promoting neuroblastoma initiation and progression. We will also define the anti-cancer efficacy of a novel therapy targeting the long non-protein-coding RNA.
Targeting JMJD6 Gene Gain For The Therapy Of Neuroblastoma
Funder
National Health and Medical Research Council
Funding Amount
$381,012.00
Summary
Cancer is the most common cause of death from disease in children. Neuroblastoma is the most prevalent solid tumour in early childhood. In this project, we will define the key role of JMJD6 gene gain in neuroblastoma cell proliferation, survival and tumourigenesis. We will also identify a novel therapeutic strategy for the treatment of neuroblastoma.
Inhibiting Tumour Growth By Targeting EphA3 And Disrupting Tumour Stromal And Vascular Microenvironment
Funder
National Health and Medical Research Council
Funding Amount
$645,136.00
Summary
Tumours consist of cancer cells, tumour blood vessels and connective tissue, all of which are different to normal tissues. Many of the cells making up tumour vessels and connective tissue are recruited, during initial growth and subsequent spreading of tumours, from the bone marrow. Our research will examine the presence and function of the EphA3 receptor on these cells during tumour development and assess how our anti-EphA3 antibody inhibits tumour growth by targeting stroma and vasculature.
FOXP3 Regulated MicroRNAs: A Novel Component Of FOXP3 Tumour Suppressor Function In Breast Epithelial Cells.
Funder
National Health and Medical Research Council
Funding Amount
$554,716.00
Summary
Until there is a cure, breast cancer research must continue to discover new targets for therapy. We have novel insight into a new tumour supressor; FOXP3, and have identified the genes it regulates in T cells. We can now apply this information to normal breast tissues to reveal the mechanism and targets that FOXP3 controls to prevent cancer
Tailoring Targeted Therapy To DNA Repair-defective High-Grade Serous Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$802,247.00
Summary
Ovarian cancer is a major cause of cancer death in women because current treatments are inadequate. Half of aggressive ovarian cancers have abnormalities in DNA repair and should be susceptible to new PARP inhibitor therapy, yet not all those respond. By developing a new model of studying human ovarian cancers in mice, we can discover markers to predict which ovarian cancers will respond best to these exciting new treatments.